Patients with HIV-infection diagnosed at late stages usually have significant immunosuppression and demand simultaneous antiretroviral therapy and treatment of opportunistic infections. The presence of HCV coinfection makes treatment even more challenging because of possible adverse effects and drug-drug interactions. HCV cure in such clinical situations not only prevents fibrosis progression, but can also enhance virologic and/or immunologic response to antiretrovirals and thus effective treatment of opportunistic infections. Thorough consideration of all existing diseases and drug interactions of the combined therapy makes simultaneous treatment of HIV, chronic hepatitis C, and opportunistic infections not only possible but the best way to improve outcomes in a complex clinical situation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3897/folmed.63.e56124 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: Elevated blood pressure (BP), even at prehypertensive levels, increases cardiovascular disease risk among people with HIV (PWH); yet international guidelines in low-income countries recommend treatment initiation at BP at least 140/90 mmHg. We determined the efficacy, feasibility, and acceptability of treating prehypertension in PWH in Haiti.
Design: An unblinded randomized clinical trial (enrolled April 2021-March 2022) with 12-month follow-up.
Unraveling distinct patterns of metagenomic surveillance and respiratory microbiota between two P1 genotypes of .
Emerg Microbes Infect
January 2025
Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, Jilin Province 130021, China.
To unravel distinct pattern of metagenomic surveillance and respiratory microbiota between () P1-1 and P1-2 and to explore the impact of the COVID-19 pandemic on epidemiological features, we conducted a multicenter retrospective study which spanned 90,886 pneumonia patients, among which 3,164 cases were identified. Our findings revealed a concurrent outbreak of , with the positivity rate rising sharply to 9.62% from July 2023, compared to the 0.
View Article and Find Full Text PDFInfluential Factors in the Treatment of Infections at a Tertiary Hospital in Vietnam.
Microb Drug Resist
January 2025
Faculty of Biotechnology, Hanoi University of Pharmacy, Hanoi, Vietnam.
As an opportunistic pathogen, is often associated with severe respiratory infections. A study conducted in an ICU of a tertiary hospital in Vietnam, where infection management is relatively good, yielded only 18 clinical isolates of over 6 months. Though the number is small, treating infections is highly complicated.
View Article and Find Full Text PDFThe anti-MRSA resource: a comprehensive archive of anti-MRSA peptides and essential oils.
J Biomol Struct Dyn
January 2025
Biochemistry and Bioinformatics Laboratory, Department of Applied Sciences, Indian Institute of Information Technology Allahabad (IIIT-A), Prayagraj, Uttar Pradesh, India.
Methicillin-resistant (MRSA), a major cause of fatalities due to Antimicrobial Resistance (AMR), can act as an opportunistic pathogen despite being part of the normal human flora. MRSA infections, such as skin infections, pneumonia, sepsis, and surgical site infections, have risen significantly, with bloodstream infection cases increasing from 21% in 2016 to 35% in 2020. This surge has prompted research into alternative treatments like nanomaterials, photodynamic therapy, antimicrobial peptides (AMPs), and essential oils (EOs).
View Article and Find Full Text PDFAIDS-related mycoses: advances, challenges, and future directions.
Trends Microbiol
January 2025
CMM AFRICA Medical Mycology Research Unit, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Medical Research Centre for Medical Mycology, University of Exeter, Exeter, Department of Biosciences, Faculty of Health and Life Sciences, Exeter, UK.
Fungal infections are a major contributor to mortality for people with HIV/AIDS. Recently, researchers, clinicians, industry experts, and policymakers convened for the triennial AIDS-Related Mycoses Meeting to address critical gaps in the management of AIDS-related mycoses. Delegates highlighted several scientifically driven milestones that have significantly reduced fungal-related deaths, and the need to address outstanding challenges in diagnosis, treatment, and research.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!